Advanced Imaging and Possible Focal Therapy for Prostate Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol. 2014;65(1):124–37.
•• Colleselli D, Schilling D, Lichy MP, et al. Topographical sensitivity and specificity of endorectal coil magnetic resonance imaging for prostate cancer detection. Urol Int. 2010;84(4): 388–94. This study reports variations in topographical MRI specificity and sensitivity based on postoperative whole-mount sections.
Anastasiadis AG, Lichy MP, Nagele U, et al. MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol. 2006;50(4):738–48.
Engelhard K, Hollenbach HP, Kiefer B, et al. Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device. Eur Radiol. 2006;16(6):1237–43.
Turkbey B, Mena E, Shih J, et al. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. Radiology. 2014;270(3):849–56.
Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004;350(22):2239–46.
Bellardita L, Rancati T, Alvisi MF, et al. Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol. 2013;64(1):30–6.
Simmons LA, Autier P, Zat’ura F, et al. Detection, localisation and characterisation of prostate cancer by prostate HistoScanning. BJU Int. 2012;110(1):28–35.
Muller BG, van den Bos W, Pinto PA, et al. Imaging modalities in focal therapy: patient selection, treatment guidance, and follow-up. Curr Opin Urol. 2014;24(3):218–24.
Smeenge M, Mischi M, Laguna Pes MP, et al. Novel contrast-enhanced ultrasound imaging in prostate cancer. World J Urol. 2011;29(5):581–7.
Ahmed HU. Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. BJU Int. 2013;111(7):1011–3.
Peng Y, Jiang Y, Antic T, et al. Validation of quantitative analysis of multiparametric prostate MR images for prostate cancer detection and aggressiveness assessment: a cross-imager study. Radiology. 2014;271(2):461–71.
Massire A, Vignaud A, Robert B, et al. Parallel-transmission-enabled three-dimensional T2-weighted imaging of the human brain at 7 Tesla. Magn Reson Med. 2014.
Nensa F, Beiderwellen K, Heusch P, et al. Clinical applications of PET/MR: current status and future perspectives. Diagn Interv Radiol. 2014;20(5):438–47.
Bauman G, Belhocine T, Kovacs M, et al. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15(1):45–55.
•• Afshar-Oromieh A, Haberkorn U, Schlemmer HP, et al. Comparison of PET/CT and PET/MRI hybrid systems using a 68 Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. Eur J Nucl Med Mol Imaging. 2014;41(5):887–97. This study uses the new PSMA PET tracer with hybrid imaging.
•• Shapiro RH, Johnstone PA. Risk of Gleason grade inaccuracies in prostate cancer patients eligible for active surveillance. Urology. 2012;80(3):661–6. In this more than one third of patients were undergraded based on their initial prostate biopsy.
Kanthabalan A, Emberton M, Ahmed HU. Biopsy strategies for selecting patients for focal therapy for prostate cancer. Curr Opin Urol. 2014;24(3):209–17.
Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol. 2010;183(2):520–7.
Kuru TH, Roethke MC, Seidenader J, et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol. 2013;190(4):1380–6.
Sonn GA, Margolis DJ, Marks LS. Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol. 2014;32(6):903–11.
Wilt TJ, Brawer MK, Jones KM, et al. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367(3):203–13.
Humphrey PA. Complete histologic serial sectioning of a prostate gland with adenocarcinoma. Am J Surg Pathol. 1993;17(5):468–72.
van den Bos W, Muller BG, Ehdaie B, et al. What is still needed to make focal therapy an accepted segment of standard therapy? Curr Opin Urol. 2014;24(3):247–55.
D’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002;95(2):281–6.
Godtman RA, Holmberg E, Khatami A, et al. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Goteborg randomised population-based prostate cancer screening trial. Eur Urol. 2013;63(1):101–7.
de la Rosette J, Ahmed H, Barentsz J, et al. Focal therapy in prostate cancer-report from a consensus panel. J Endourol. 2010;24(5):775–80.
Liu W, Laitinen S, Khan S, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med. 2009;15(5):559–65.
Anderson ES, Margolis DJA, Mesko S, et al. Multiparametric MRI identifies and stratifies prostate cancer lesions: implications for targeting intraprostatic targets. Brachytherapy. 2014;13(3):292–8.
Cornud F, Khoury G, Bouazza N, et al. Tumor target volume for focal therapy of prostate cancer—does multiparametric magnetic resonance imaging allow for a reliable estimation? J Urol. 2014;191(5):1272–9.
Bomers JG, Sedelaar JP, Barentsz JO, et al. MRI-guided interventions for the treatment of prostate cancer. AJR Am J Roentgenol. 2012;199(4):714–20.
Napoli A, Anzidei M, De Nunzio C, et al. Real-time magnetic resonance-guided high-intensity focused ultrasound focal therapy for localised prostate cancer: preliminary experience. Eur Urol. 2013;63(2):395–8.
Crouzet S, Rouviere O, Martin X, et al. High-intensity focused ultrasound as focal therapy of prostate cancer. Curr Opin Urol. 2014;24(3):225–30.
Rouviere O, Glas L, Girouin N, et al. Prostate cancer ablation with transrectal high-intensity focused ultrasound: assessment of tissue destruction with contrast-enhanced US. Radiology. 2011;259(2):583–91.